Mymee, a pioneer in digital care programs for people with autoimmune disease, today announced the widespread release of its program for people with COVID long haul, or Post-acute COVID syndrome. Mymee's program is the first remote, self-care program specifically tailored to address the extreme symptoms resembling autoimmunity in people who have recovered from the virus.
COVID-19 experts predict that 10 - 35% of both asymptomatic and symptomatic COVID-19 cases are likely to develop some form of COVID long haul: This suggests 10 million people in the U.S. may already be dealing with common symptoms such as fatigue, brain fog, anxiety, joint or muscle pain, memory loss, shortness of breath and/or a myriad of other potential symptoms that may impact quality of life, productivity, and emotional wellbeing.
Several published research studies have begun to draw links between COVID long haul and systemic autoimmune diseases such as Lupus and Rheumatoid Arthritis; in which the immune system overreacts and attacks the body's own cells. As with Autoimmune disease, COVID Long Haul appears to affect women at a rate of 2 to 1 compared to men. This adds to past independent studies published by the NIH and Stanford, which cite the role environmental factors such as viruses, nutrition, contaminants, and stress, can play in triggering autoimmunity.
"Viruses like COVID-19 are a known trigger for autoimmunity," said Mette Dyhrberg CEO and founder of Mymee, "In the pilot program, one of the commonalities we saw with systemic autoimmune diseases is that each COVID long haul case can involve multiple triggers and symptoms throughout the body. It is very hard for an individual to isolate even one trigger responsible for autoimmune reactions without help, let alone trying to correlate multiple combinations of symptoms and triggers. Mymee was built to simplify this process and help individuals find their triggers, so they can gain back control of their health and their lives."
The Mymee COVID Long Haul program began as pilot in June 2020, following the first wave of the COVID-19 crisis in New York, where 1.7 million were infected with the virus. At the time Mymee worked closely with Mount Sinai Hospital in New York, where both are based, to share insights and develop a collaborative approach to addressing the rising numbers of COVID long haul cases. Mymee moved quickly to adapt its commercially validated autoimmunity program for COVID long haul and started enrollment at the same time that Mount Sinai launched its Post-COVID Care Clinic.
"Mymee has been reporting great success with management of patients showing signs and symptoms of post-acute COVID Syndrome, struggling with a host of unresolved, debilitating symptoms. Interestingly, most of these patients were not hospitalized at the time of infection and are only now approaching groups like Mount Sinai to request medical attention," said Dr. David Putrino, Director of Rehabilitation Innovation at Mount Sinai, "As one of the first companies to identify patients with post-acute COVID Syndrome (also called COVID "long haulers") as a potential issue following acute COVID-19 infection, Mymee has joined the trusted performance network at Mount Sinai's Department of Rehabilitation and Human Performance, providing an important support system for those seeking help."
Mymee's platform was commercially validated on unique cases of autoimmunity, including lupus, RA, Crohn's, and rare or undefined autoimmune disorders like COVID long haul, with over 150 symptoms and over 90 potential triggers identified, and thousands of combinations of both.
Mymee is offering a free consult for individuals seeking support for their long-haul symptoms. The full program includes a bespoke mobile app that is customized to each individual and makes it simple for anyone to capture their unique symptoms and trigger data within five minutes a day. A dedicated Mymee health coach who overcame their own autoimmunity and is certified on Mymee's data platform provides personalized support throughout the process of identifying triggers, reducing symptoms, and regaining quality of life. Access to daily breathing sessions is also included.